北京依生兴业科技有限公司 Yisheng Pharma
{{company.company_channel.channel_name}}
{{company.company_name_local}}
{{company.company_channel.channel_name}}
YS Biopharma Announces Unaudited Financial Results for the First Nine Months of Fiscal Year 2024 2024-04-19 19:00
YS Biopharma Granted Phase I Clinical Trial License of Therapeutic Chronic Hepatitis B Virus Vaccine 2024-04-18 20:00
YS Biopharma to Report First Nine Months of Fiscal Year 2024 Financial Results on April 19, 2024 2024-04-16 20:00
YS Biopharma Announces Positive Interim Results of Pivotal Phase 3 Clinical Study of PIKA Rabies Vaccine 2024-04-09 20:00
YS Biopharma Announces Full Repayment of US$40,000,000 Loan Facility 2024-04-03 20:00
YS Biopharma Announces Board Changes and Strategic Leadership Appointments in Chinese Subsidiaries 2024-03-05 21:00
YS Biopharma Announces Appointment of New Directors 2024-02-14 20:50
YS Biopharma Announces US$40 Million Private Placement Financing 2024-02-09 19:30
YS Biopharma Announces Unaudited Financial Results for the First Half of Fiscal Year 2024 2024-01-23 06:00
YS Biopharma Announces Changes to its Board Committees 2024-01-08 21:00
YS Biopharma Responds to Unauthorized Press Release Regarding Extraordinary General Meeting 2023-12-21 05:30
/DISREGARD RELEASE: YS Biopharma/ 2023-12-21 05:15
Noble Capital Markets Initiates Coverage on YS Biopharma With Outperform Rating and US$5.25 Price Target 2023-11-14 21:30
YS Biopharma Announces Completion of Subject Enrollment in Pivotal Phase 3 Clinical Trial of PIKA Rabies Vaccine 2023-10-31 20:30
YS Biopharma Announces Receipt of Nasdaq Notice 2023-10-26 20:30
YS Biopharma Announces First Subject Enrollment in Pivotal Phase 3 Clinical Trial of PIKA Rabies Vaccine 2023-09-26 20:30
YS Biopharma Granted Patent in the U.S. for Immunotherapy Targeting Chronic Hepatitis B Virus Infection 2023-09-15 20:30
YS Biopharma to Participate in Citi's 18th Annual Biopharma Conference 2023-09-05 20:30
YS Biopharma Announces Purchase of Shares by Company Officers 2023-08-25 04:15
YS Biopharma Announces Unaudited Financial Results for the First Quarter of Fiscal Year 2024 2023-08-16 05:00
1 2 3